LifeVantage Corp. Stock Hits New 52-Week Low at $9.28

LifeVantage Corp., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 9.28 on October 6, 2025. This significant decline highlights the stock's recent struggles, especially as it has underperformed compared to the broader market, with a one-year return of -16.58% against the S&P 500's 17.82%.
Despite the recent downturn, LifeVantage Corp. has shown some positive financial metrics. The company boasts a return on equity (ROE) of 28.30%, indicating strong management efficiency. Additionally, it maintains a low debt-to-equity ratio of -0.53, suggesting a solid financial position. The company has also reported a notable increase in net profit for the first half of the year, growing by 83.16% to USD 5.43 million.

However, the stock's performance over the past year has been overshadowed by a decline in operating profit, which has decreased at an annual rate of -5.22% over the last five years. With a market capitalization of USD 145 million and a price-to-book ratio of 4.19, LifeVantage Corp. continues to navigate a challenging market landscape.